Teclistamab-cqyv significantly improves PFS and OS in multiple myeloma patients with 1 to 3 prior therapies, showing a 71% ...

The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.

Suvemcitug combined with chemotherapy significantly improved PFS and OS in platinum-resistant recurrent ovarian cancer, nearly doubling median PFS and extending median OS. The trial demonstrated ...

Patients with multiple myeloma (MM) who have high-risk cytogenetic abnormalities typically have shorter progression-free survival (PFS) and overall survival (OS) compared with standard-risk patients.

Findings showed datopotamab deruxtecan significantly improved PFS and OS vs chemotherapy. Topline data were announced from a phase 3 trial evaluating datopotamab deruxtecan-dlnk as a first-line ...

Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, first-in-class PD-1/VEGF bispecific ...

Evaluating CR as a surrogate endpoint for PFS in R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A meta-analysis of randomized controlled trials (RCT). CR/CRi (vs non-CR/CRi) ...

The addition of lurbinectedin to atezolizumab improved survival for certain adults with lung cancer, according to the agent’s manufacturer. Lurbinectedin (Zepzelca; Jazz Pharmaceuticals, PharmaMar) is ...

DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...

Accrual in this trial was suspended in March 2025 as a result of findings from the Checkmate 8HW trial, which showed that the ...